Introduction
Early gastric cancer (EGC) is defi ned as invasion confi ned to the mucosa or submucosa, regardless of the presence of regional lymph node metastasis. In recent years, the incidence of EGC has reached more than 50% of all gastric cancer cases in Japan. Gastrectomy with D2 lymphadenectomy had been fi rmly accepted as a standard treatment for every stage of gastric cancer since the 1980s [1, 2] . EGC treated with radical surgery has an excellent survival rate, with 5-year survival rates of more than 90% being reported by both Western [3] and Japanese [4] investigators. However, ever since the clinicopathological features of EGC, such as the incidence of lymph node metastasis, were clarifi ed in the late 1990s, gastrectomy with D2 lymphadenectomy for all patients with EGC has come to be considered as an overtreatment [5] [6] [7] [8] .
The gastric cancer treatment guidelines (Guidelines) were issued by the Japanese Gastric Cancer Association (JGCA) in March 2001 [9, 10] . The Guidelines were designed to provide standard indications for the selection of treatments for gastric cancer according to the clinical stages of the disease (JGCA classifi cation). The Guidelines allowed endoscopic resection and a modifi ed gastrectomy as treatment modalities for EGC, in addition to a standard gastrectomy. Endoscopic treatment can be utilized in patients with a minimal chance of lymph node metastasis. A modifi ed gastrectomy, including limited lymphadenectomy, can be utilized in patients with EGC beyond the inclusion criteria for endoscopic treatment. Because patients with a minimal chance of lymph node metastasis were excluded as candidates for a gastrectomy, Japanese surgeons are interested in whether surgeons are actually facing an increasing number of EGC cases with a greater chance of lymph node metastasis. Furthermore, whether a modifi ed gastrectomy with a reduced extent Abstract Background. The gastric cancer treatment guidelines (Guidelines) of the Japanese Gastric Cancer Association allow endoscopic treatment and a modifi ed gastrectomy for the treatment of early gastric cancer (EGC). Endoscopic treatment is indicated for EGC with a minimal chance of nodal metastasis. Consequently, surgeons will likely treat an increasing number of EGC patients with greater chance of nodal metastasis using a reduced extent of lymphadenectomy. The aim of this study was to investigate the trends in characteristics and long-term oncological outcomes of surgically treated EGC patients after the introduction of the Guidelines. Methods. Between 2001 and 2003, 696 patients underwent a gastrectomy according to the Guidelines. These 696 patients (the Guidelines group) were retrospectively compared with 635 patients (the control group) who had undergone a gastrectomy between 1991 and 1995 (before the introduction of the Guidelines). Results. The incidence of nodal metastasis in mucosal cancers was higher in the Guidelines group than in the control group (6.5% vs 2.6%). The proportion of D2 or greater extended lymphadenectomy in the Guidelines group was lower than that in the control group (29.7% vs 62.5%). Nevertheless, the 5-year survival rate in the Guidelines group was similar to that in the control group (94.2% vs 92.3%). Conclusion. Surgeons treated more cases of mucosal cancer with nodal metastasis after the introduction of the Guidelines. The long-term oncological outcomes for patients with EGC remained excellent. So far, the Guidelines for the treatment of EGC appear acceptable.
of lymphadenectomy is suffi cient treatment for these cases of EGC with a greater chance of lymph node metastasis is also a topic of interest. We retrospectively investigated the clinicopathological characteristics and long-term oncological outcomes of EGC patients who underwent a gastrectomy after the introduction of the Guidelines and compared our results with those obtained in patients treated before the introduction of the Guidelines.
Patients and methods

Patients
Between January 1991 and December 2003, 2218 patients with EGC underwent a gastrectomy with curative intent at the National Cancer Center Hospital, Tokyo. Between March 2001 and December 2003, 696 of these patients underwent a gastrectomy according to the Guidelines. These 696 patients (the Guidelines group) were retrospectively compared with 635 patients (the control group) who had undergone a gastrectomy between January 1991 and December 1995 (before the introduction of the Guidelines). Patients who had undergone a gastrectomy between January 1996 and February 2001 were excluded from this analysis because endoscopic resection and a modifi ed gastrectomy for EGC were frequently performed as investigational treatments during this period. Surgical specimens were examined and scored according to the Japanese classification of gastric carcinoma [9] . The vital statistics for all the patients were obtained from the city registry offi ce and the follow-up records. All the patients were followed up for at least 5 years.
Surgical procedures
Before the introduction of the Guidelines, a gastrectomy with D2 lymphadenectomy was performed as a standard treatment for every stage of gastric cancer. After the introduction of the Guidelines, defi nite recommendations for endoscopic treatment were confi ned to tumors in the mucosal layer; type I, IIa, or depressed type IIc with no ulcers; well-or moderately differentiated adenocarcinoma; and tumors smaller than 2 cm. A modifi ed gastrectomy was utilized in patients with cT1N0 (stage IA) tumors and cT1N1 (stage IB) tumors less than 2.0 cm in size, excluding patients who fulfi lled the criteria for endoscopic resection. The modifi ed gastrectomy allowed a reduced extent of lymphadenectomy, compared with a D2 lymphadenectomy. While the N1 nodes were completely removed, some suprapancreatic N2 nodes, such as the node along the splenic artery, were excluded from the dissection.
Statistical analysis
Statistical analysis was performed using SPSS for Windows version 17.0 (SPSS, Chicago, IL, USA). The signifi cance of the differences in the patients' clinicopathological features and the incidence of lymph node metastasis were determined using the χ 2 test and the Mann-Whitney U-test, as appropriate. A 5% significance level (P < 0.05) was considered statistically signifi cant. The survival rate was calculated by the Kaplan-Meier method with 95% confi dence intervals (CIs), and the hazard ratio was calculated by the Cox proportional hazards model with 95% CIs.
Results
Patient characteristics
The male-to-female ratio in the Guidelines group (1.92: 1) was signifi cantly lower than that in the control group (2.55: 1; Table 1 ). The median age in the Guidelines group (62 years) was signifi cantly higher than that in the control group (60 years). There was no difference in the distribution of tumor location. The median tumor size in the Guidelines group (30.0 mm) was signifi cantly larger than that in the control group (26.0 mm). The proportion of undifferentiated-type lesions in the Guidelines group (58.0%) was signifi cantly higher than that in the control group (41.7%).
The incidence of lymph node metastasis in patients with mucosal cancers in the Guidelines group (6.5%) was signifi cantly higher than that in the control group (2.6%; Table 2 ). No difference in the incidence of lymph node metastasis in patients with submucosal cancer was noted between the two groups. The proportion of D2 or greater extended lymphadenectomy in the Guidelines group (207/696; 29.7%) was signifi cantly lower than that in the control group (397/635; 62.5%).
Survival
The median follow-up period in the Guidelines group was 5.5 years, while that in the control group was 7.5 years. During a 5-year follow-up period, 40 patients (5.7%) in the Guidelines group died; 9 of these patients (1.3%) died from recurrence. Thirty-eight patients in the control group (6.0%) died; 6 of these patients (0.9%) died from recurrence. The overall 5-year survival rates were 94.2% (95% CI, 92.4%-96.0%) in the Guidelines group and 92.3% (95% CI, 90.1%-94.5%) in the control group. If the relative risk for death was set at one for patients in the control group, the hazard ratio in the Guidelines group was 0.78 (95% CI, 0.53-1.15) for overall patients. The overall 5-year survival rates for the patients with mucosal cancer were 95.1% (95% CI, 92.8%-97.5%) in the Guidelines group and 93.7% (95% CI, 91.0%-96.4%) in the control group. The hazard ratio in the Guidelines group was 0.83 (95% CI, 0.44-1.58) for patients with mucosal cancer. The overall 5-year survival rates for the patients with submucosal cancer were 93.5% (95% CI, 91.0%-96.0%) in the Guidelines group and 91.0% (95% CI, 87.9%-94.1%) in the control group. The hazard ratio in the Guidelines group was 0.74 (95% CI, 0.46-1.19) for patients with submucosal cancer.
Discussion
The Guidelines allow endoscopic treatment and a modifi ed gastrectomy for EGC. Candidates for endoscopic treatment include patients with small differentiatedtype mucosal cancers. When these tumors were excluded from the indications for gastrectomy, the tumor size in the Guidelines group was larger and the proportion of undifferentiated-type lesions was greater in the Guidelines group, compared with these parameters in the control group, as expected.
The male-to-female ratio was signifi cantly lower in the Guidelines group than in the control group. Differentiated-type carcinomas are more common among men than among women [11] . Because male patients tend to fulfi ll the criteria for endoscopic resection more commonly than female patients, more men may have undergone endoscopic treatment. The median age was also slightly higher in the Guidelines group. Considering that differentiated-type tumors, which are occasionally treated using endoscopy, are more common among elderly patients [12, 13] , a lower median age in the Guidelines group would not be unexpected. However, the opposite result was obtained. This result might Guidelines, gastric cancer treatment guidelines of the Japanese Gastric Cancer Association refl ect an increase in the number of elderly patients themselves as a result of the prolonged life expectancy in Japan. The incidence of lymph node metastasis in mucosal cancers was reported to be 1.2%-3.3% [6, [14] [15] [16] [17] , and all of these patients with EGC underwent a standard gastrectomy. In the present study, the incidence of lymph node metastasis in mucosal cancers in the control group was similar to those study fi ndings (2.6%), while that in the Guidelines group was signifi cantly higher (6.5%). The reason for this difference is easily interpreted. After the introduction of the Guidelines, endoscopic resection was established as the standard therapy for EGC in patients with a negligible risk of lymph node metastasis; therefore, the incidence of surgically treated patients with lymph node metastasis increased.
The Guidelines recommend D2 gastrectomy only in selected patients. As a result, the proportion of patients undergoing gastrectomy with D2 or greater extended lymphadenectomy was signifi cantly smaller in our Guidelines group (29.7%) than in the control group (62.5%). Nevertheless the 5-year survival rate in the Guidelines group (94.2%) was similar to that in the control group (92.3%) and was also similar to that for patients undergoing gastrectomy with D2 lymphadenectomy in previous reports [18, 19] .
In conclusion, surgeons treated more cases of mucosal cancer with lymph node metastasis after the introduction of the Guidelines. The long-term oncological outcomes for patients with EGC remained excellent after the introduction of the modifi ed operation. So far, the Guidelines for the treatment of EGC appear acceptable.
